Markets are Closed
MYL
Mylan N.V.
Open
Previous Open
High
Previous High
Low
Previous Low
Close
Previous Close
Volume
Previous Volume
Company Profile
Description
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.
Exchange
Nasdaq Global Select
List Date
January 02, 1990
CEO
Heather Bresch
Employees
33,417
Related Stocks
Financials
Revenue
11.50B
Earnings
671.70M
13B
9B
6B
3B
518M
2015
2016
2017
2018
Splits
| October 09, 2003 | 0.67% |
| January 28, 2003 | 0.67% |
Dividends
| July 16, 2007 | $0.06 |
| April 16, 2007 | $0.06 |
| January 16, 2007 | $0.06 |
| October 16, 2006 | $0.06 |
| July 14, 2006 | $0.06 |
| April 17, 2006 | $0.06 |
| January 13, 2006 | $0.06 |
| October 17, 2005 | $0.06 |
| July 15, 2005 | $0.06 |
| April 15, 2005 | $0.03 |
| January 14, 2005 | $0.03 |
| October 15, 2004 | $0.03 |
| July 15, 2004 | $0.03 |
| April 15, 2004 | $0.03 |
| January 15, 2004 | $0.03 |
| October 15, 2003 | $0.03 |
| July 15, 2003 | $0.03 |
| April 15, 2003 | $0.03 |
| January 15, 2003 | $0.05 |
| September 26, 2002 | $0.04 |
| June 26, 2002 | $0.04 |
| March 26, 2002 | $0.04 |
| December 27, 2001 | $0.04 |
| September 26, 2001 | $0.04 |
| June 27, 2001 | $0.04 |
| March 28, 2001 | $0.04 |
| December 27, 2000 | $0.04 |
| October 15, 2000 | $0.04 |
Related News
Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
Mar 27, 2020 @ 13:30
Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto®, a biosimilar to Enbrel® (etanercept), for all indications of the reference...
finance yahoo
Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs
Mar 25, 2020 @ 17:30
Mylan (NASDAQ: MYL) today announced that, in its ongoing effort to support patients and public health needs in the current unprecedented circumstances surrounding the COVID-19 pandemic, Mylan has voluntarily waived its exclusive rights in the U.S. to distribute its generic version of Kaletra® (lopinavir...
finance yahoo
Dow Jones Today, Stocks Edge Up; Coronavirus Stimulus Plans In Motion As California, Pennsylvania Lock Down
Mar 20, 2020 @ 13:51
Mylan, Co-Diagnostics and Moderna led an early stock futures rebound, and Microsoft topped the Dow Jones, as stimulus plans boosted investor optimism....
finance yahoo
Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?
Feb 20, 2020 @ 17:31
Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
finance yahoo
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
Feb 18, 2020 @ 14:02
Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results....
finance yahoo
Mylan to Release 2019 Fourth Quarter, Full Year Results and 2020 Guidance on Feb. 27, 2020
Feb 18, 2020 @ 12:30
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2019 financial results, as well as its 2020 financial guidance, on Thursday, Feb. 27, after the close of the U.S. financial markets. The company also will host a webcast at 4:30...
finance yahoo
Pharma Stock's Rally Could Have Legs
Feb 14, 2020 @ 17:00
A bull signal flashing for MYL could give its recent rally a big boost...
finance yahoo
Mylan Breaks Out on the Upside From a 9-Month Base Pattern
Feb 06, 2020 @ 15:10
In this daily bar chart of MYL, below, we can see how prices have moved sideways since May. Dips to and below $18 have been bought. This moving average crossover signal is typically bullish but often late. The daily On-Balance-Volume (OBV) line has moved up and down with the price action the past eight months but it is not far from making a new high for the move up....
finance yahoo
Biogen shares rise as drugmaker avoids ‘worst case scenario’ in patent dispute
Feb 06, 2020 @ 11:37
One of Massachusetts’ biggest drugmakers may have two more contests coming down the pipeline over its best-selling drug, but at least one analyst believes the company avoided the “worst case scenario” this week....
finance yahoo
Biogen Rockets Into A Breakout After Beating Mylan In A Patent Battle
Feb 05, 2020 @ 21:21
Biogen stock rocketed Wednesday after U.S. patent officials agreed to uphold a key patent covering Tecfidera for several more years. Tecfidera is an important multiple sclerosis drug....
finance yahoo